Different antibody patterns separate latent and active childhood TB

Tuberculosis caused by Mtb remains a leading infectious killer of children worldwide, and diagnosing TB in kids is especially difficult. Children are more likely than adults to progress to severe disease, and symptoms often overlap with other lower respiratory infections. To better understand whether different pediatric outcomes reflect distinct immune responses, Christina Lancioni and colleagues set out to map antibody patterns across a range of disease states. They studied children who presented with symptoms of active TB (ATB), children with evidence of latent TB infection (LTBI), and children whose illness was a non-TB lower respiratory tract infection (non-TB LRTI). Rather than focusing only on T cells or a single antibody, the team measured responses to about four dozen Mtb antigens to get a broad view of humoral immunity. By comparing groups across the spectrum from infection to disease, the researchers aimed to see whether specific antibody types, receptor interactions, or antibody-driven functions could distinguish active disease from latent infection and from other respiratory illnesses in children.

To profile these antibody signatures the investigators used a custom Luminex assay to measure Mtb-specific antibody subclass/isotype, Fc receptor (FcR) binding profiles, and functions across the pediatric groups. The approach captured diverse features of humoral immunity, not just antibody quantity but how antibodies engage immune cells. The study found a robust humoral immune response in children with ATB compared to non-TB LRTI, marked by a strong IgA response that exhibited high FcαR binding. In contrast, children with LTBI showed Mtb-specific antibodies with enhanced opsinophagocytic FcγR2A binding, and their antibodies had a higher capacity to activate NK cells and neutrophils. These differences were consistent across the panel of Mtb antigens tested, suggesting distinct functional antibody profiles accompany latent versus active infection in children.

The findings show significant differences in antibody-based immunity across the landscape of pediatric TB, differences that could influence how well a child controls mycobacterial infection. A strong IgA/FcαR signature with active disease and an opsinophagocytic FcγR2A/NK cell and neutrophil-activating signature with latent infection point to measurable biomarkers that could help clinicians separate ATB from LTBI and from other respiratory infections. Because the study assessed both binding properties and cell-activating functions, it highlights not only markers that might improve diagnosis but also mechanisms that could be targeted by novel therapies or vaccines aimed at promoting protective antibody functions. Funded by the US National Institutes of Health, the research suggests a practical path toward tests and interventions that use antibody quality, not just quantity, to better manage pediatric tuberculosis.